0001035422 2026-01-01 2026-06-30 0001035422 ctth:MexicoCountryMember 2026-01-01 2026-06-30 0001035422 ctth:EuropeCountryMember 2026-01-01 2026-06-30 0001035422 ctth:UsTwoCountryMember 2026-01-01 2026-06-30 0001035422 ctth:CanadaOneCountryMember 2026-01-01 2026-06-30 0001035422 ctth:UsOneCountryMember 2026-01-01 2026-06-30 0001035422 ctth:CanadaCountryMember 2026-01-01 2026-06-30 0001035422 ctth:UsCountryMember 2026-01-01 2026-06-30 0001035422 ctth:RyanKhouriMember 2026-01-01 2026-03-31 0001035422 ctth:PetroCzupielMember 2024-01-01 2024-12-31 0001035422 ctth:AllenGreenspoonMember 2024-01-01 2024-12-31 0001035422 ctth:FrankHaritonMember 2025-01-01 2025-12-31 0001035422 ctth:BordersConsultingLLCMember 2025-01-01 2025-12-31 0001035422 ctth:MurrayGoldenbergMember 2025-01-01 2025-12-31 0001035422 ctth:KevinSakserMember 2025-01-01 2025-12-31 0001035422 ctth:KevinSakserMember 2024-01-01 2024-12-31 0001035422 ctth:RyanKhouriMember 2024-01-01 2024-12-31 0001035422 ctth:JohnJenneweinMember 2024-01-01 2024-12-31 0001035422 ctth:RyanKhouriMember 2025-01-01 2025-12-31 0001035422 ctth:KatherineColeMember 2025-01-01 2025-12-31 0001035422 ctth:KatherineColeMember 2026-01-01 2026-03-31 0001035422 ctth:KevinSakserMember 2026-01-01 2026-03-31 0001035422 2024-01-01 2024-12-31 0001035422 2026-01-01 2026-03-31 0001035422 2025-01-01 2025-12-31 0001035422 us-gaap:TrademarksMember 2026-01-01 2026-06-30 0001035422 us-gaap:PatentsMember 2026-01-01 2026-06-30 0001035422 us-gaap:RetainedEarningsMember 2026-06-30 0001035422 us-gaap:TreasuryStockCommonMember 2026-06-30 0001035422 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001035422 us-gaap:CommonStockMember 2026-06-30 0001035422 us-gaap:RetainedEarningsMember 2026-01-01 2026-06-30 0001035422 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-06-30 0001035422 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-06-30 0001035422 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001035422 us-gaap:RetainedEarningsMember 2025-12-31 0001035422 us-gaap:TreasuryStockCommonMember 2025-12-31 0001035422 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001035422 us-gaap:CommonStockMember 2025-12-31 0001035422 2025-06-30 0001035422 us-gaap:RetainedEarningsMember 2025-06-30 0001035422 us-gaap:TreasuryStockCommonMember 2025-06-30 0001035422 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001035422 us-gaap:CommonStockMember 2025-06-30 0001035422 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001035422 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001035422 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001035422 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-06-30 0001035422 2024-12-31 0001035422 us-gaap:RetainedEarningsMember 2024-12-31 0001035422 us-gaap:TreasuryStockCommonMember 2024-12-31 0001035422 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001035422 us-gaap:CommonStockMember 2024-12-31 0001035422 2025-01-01 2025-06-30 0001035422 2025-12-31 0001035422 2026-06-30 0001035422 2026-09-11 iso4217:USD shares iso4217:USD shares 0001035422 false --12-31 Q2 2026

0.0001

300000000

59722232

0.0001

10000000

false false false false 10800 10-Q true 2026-06-30 false 333-292497 CTT PHARMACEUTICAL HOLDINGS, INC. FL 11-3763974 1646 W Snow Avenue Suite 138 Tampa FL 33606 813 606-0060 Yes Yes Non-accelerated Filer true true false false 59722232

15359

67403

70809

67403

70809

67434

86168

21949 12204

19442

18814

41391

31018

0.0001

10000000

0.0001

300000000

59722232

58837232

5973

5884

7671441

7600729

-7651371

-7551463

26043

55150

67434

86168

71711 60210

9123

5621

11407

21242

628

37 0 2779 0 409 0

408

3406

3200

99908

90273

-99908

-90273

-0.00

59045065

57271737

58837232

5884

7600729

-7551463

55150

-99908

750000

59925

60000

135000 14 10787 0 0 10801

59722232

5973

7671441

-7651371

26043

54069337

5407

7422332

-7395556

32183

-90273

1100000

110

60120

60230

2157895 215 79784 0 0 79999

57327232

5732

7562236

-7485829

82139

-99908

-90273

3406

3200

60000

60120

9745

-21300

628

470

-26129

-47783

10787 79784

325

10801

80109

-15328

32326

15359

114

32440

NOTE 1 - NATURE OF OPERATIONS CTT Pharmaceutical Holdings, Inc. (the “Company”) is a Delaware C-Corporation formed in 1996. The Company specializes in drug delivery systems technology within the pharmaceutical industry. The Company is focused on fast-dissolving drug delivery systems through the development of advanced oral methods.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of accounting The financial statements of the Company have been prepared on the accrual basis of accounting, which conforms to accounting principles generally accepted in the United States of America (U.S. GAAP). Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Financial instruments The Company’s balance sheets may include the following financial instruments: cash, related-party payables, and related-party note payables. The carrying amount of current assets and current liabilities approximate their fair value due to the relatively short period of time between the origination of these instruments and their expected realization. Revenue recognition As of June 30, 2026, and December 31, 2025, the Company had no revenue-producing activities. The Company recognizes revenue as it satisfies contractual performance obligations by transferring promised goods or services to its customers. The amount of revenue recognized reflects the consideration the Company expects to be entitled to in exchange for those promised goods or services. A good or service is transferred to a customer when, or as, the customer obtains control of that good or service. Earnings per share Basic earnings per share are computed using the weighted average number of common shares outstanding at June 30, 2026 and December 31, 2025, respectively. Diluted earnings per share reflect the potential dilutive effects of common stock equivalents such as options, warrants and convertible securities. Given the historical and projected future losses of the Company, all potentially dilutive common stock equivalents are considered anti-dilutive. Concentrations of credit risk The Company maintains cash in bank accounts at high credit quality United States financial institutions. At various times during the six months ended June 30, 2026 and the year ended December 31, 2025, the Company may have had cash on deposit with financial institutions in excess of federal depository insurance limits. The Company has not experienced and does not anticipate any credit losses on these deposits. Subsequent events CTT Pharma received approval for a CIP Application from the United States Patent Office utilizing CTT’s technology for a Nicotine Strip. CTT Pharma signed an LOI with a company in Europe to potentially form a partnership. It’s important to note that discussions are in the early stages and may or may not move towards a partnership. The Company has evaluated subsequent events occurring through August 7, 2026, which is the date the financial statements were issued. Cash and cash equivalents For purposes of reporting cash flows, the Company considers all liquid instruments purchased with an original maturity of three months or less to be cash equivalents. There were no cash equivalents as of June 30, 2026 and December 31, 2025. Related-party payables Related-party payables consist of funds advanced from a related party to the Company on terms equivalent to those that prevail in arm’s length transactions. During the six months ended June 30, 2026, the company repaid funds which were advanced by Ryan Khouri, as working capital and as part of a management contract, on an as-needed basis. The ending payable to Ryan Khouri at June 30, 2026 was $21,949. Related-party note payable Related-party notes consist of uncollateralized obligations of funds advanced to the Company by a related party on terms equivalent to those that prevail in arm’s length transactions. There were no such advances during the first six months of 2026 or 2025. The advances are planned to be repaid through the issuance of common restricted shares and are not formalized nor interest bearing. Share-based compensation The Company, from time to time, may issue stock options, warrants and restricted stock as compensation to employees, directors, officers and affiliates, as well as to acquire goods or services from third parties. ln all cases, the Company calculates share-based compensation using the Black-Scholes option pricing model and expenses awards based on fair value at the grant date, which in the case of third-party suppliers is the shorter of the period over which services are to be received or the vesting period, and for employees, directors, officers and affiliates is typically the vesting period. Share-based compensation is included in consulting fees on the income statements. Advertising Advertising costs are expensed as incurred and are included in operating expenses on the income statements. Income taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires an asset and liability approach for financial accounting and reporting of income taxes. Deferred income taxes reflect the impact of temporary differences between the amount of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. Deferred tax assets, if any, include tax loss and credit carryforwards and are reduced by a valuation allowance if, based on available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Intangible assets The Company’s intangible assets consist of trademarks and patents held across multiple countries. The patents are amortized over their useful lives, typically up to 20 years, which is the standard patent expiration period. The trademarks are amortized over their useful lives, typically up to 15 years. Costs associated with patents that have not yet received a grant number are typically recorded as deferred patent costs, and upon receipt of a grant number, are amortized.

The financial statements of the Company have been prepared on the accrual basis of accounting, which conforms to accounting principles generally accepted in the United States of America (U.S. GAAP).

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The Company’s balance sheets may include the following financial instruments: cash, related-party payables, and related-party note payables. The carrying amount of current assets and current liabilities approximate their fair value due to the relatively short period of time between the origination of these instruments and their expected realization.

As of June 30, 2026, and December 31, 2025, the Company had no revenue-producing activities. The Company recognizes revenue as it satisfies contractual performance obligations by transferring promised goods or services to its customers. The amount of revenue recognized reflects the consideration the Company expects to be entitled to in exchange for those promised goods or services. A good or service is transferred to a customer when, or as, the customer obtains control of that good or service.

Basic earnings per share are computed using the weighted average number of common shares outstanding at June 30, 2026 and December 31, 2025, respectively. Diluted earnings per share reflect the potential dilutive effects of common stock equivalents such as options, warrants and convertible securities. Given the historical and projected future losses of the Company, all potentially dilutive common stock equivalents are considered anti-dilutive.

The Company maintains cash in bank accounts at high credit quality United States financial institutions. At various times during the six months ended June 30, 2026 and the year ended December 31, 2025, the Company may have had cash on deposit with financial institutions in excess of federal depository insurance limits. The Company has not experienced and does not anticipate any credit losses on these deposits.

CTT Pharma received approval for a CIP Application from the United States Patent Office utilizing CTT’s technology for a Nicotine Strip. CTT Pharma signed an LOI with a company in Europe to potentially form a partnership. It’s important to note that discussions are in the early stages and may or may not move towards a partnership. The Company has evaluated subsequent events occurring through August 7, 2026, which is the date the financial statements were issued.

For purposes of reporting cash flows, the Company considers all liquid instruments purchased with an original maturity of three months or less to be cash equivalents. There were no cash equivalents as of June 30, 2026 and December 31, 2025.

Related-party payables consist of funds advanced from a related party to the Company on terms equivalent to those that prevail in arm’s length transactions. During the six months ended June 30, 2026, the company repaid funds which were advanced by Ryan Khouri, as working capital and as part of a management contract, on an as-needed basis. The ending payable to Ryan Khouri at June 30, 2026 was $21,949. Related-party notes consist of uncollateralized obligations of funds advanced to the Company by a related party on terms equivalent to those that prevail in arm’s length transactions. There were no such advances during the first six months of 2026 or 2025. The advances are planned to be repaid through the issuance of common restricted shares and are not formalized nor interest bearing.

The Company, from time to time, may issue stock options, warrants and restricted stock as compensation to employees, directors, officers and affiliates, as well as to acquire goods or services from third parties. ln all cases, the Company calculates share-based compensation using the Black-Scholes option pricing model and expenses awards based on fair value at the grant date, which in the case of third-party suppliers is the shorter of the period over which services are to be received or the vesting period, and for employees, directors, officers and affiliates is typically the vesting period. Share-based compensation is included in consulting fees on the income statements.

Advertising costs are expensed as incurred and are included in operating expenses on the income statements.

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires an asset and liability approach for financial accounting and reporting of income taxes. Deferred income taxes reflect the impact of temporary differences between the amount of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. Deferred tax assets, if any, include tax loss and credit carryforwards and are reduced by a valuation allowance if, based on available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company’s intangible assets consist of trademarks and patents held across multiple countries. The patents are amortized over their useful lives, typically up to 20 years, which is the standard patent expiration period. The trademarks are amortized over their useful lives, typically up to 15 years. Costs associated with patents that have not yet received a grant number are typically recorded as deferred patent costs, and upon receipt of a grant number, are amortized.

P20Y P15Y

NOTE 3 - GOING CONCERN Historically, the Company has experienced, and the Company continues to experience, net losses from operations, negative cash flow from operating activities, and working capital deficits. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date of issuance of the audited financial statements. The Company has not yet begun principal operations, and therefore, net losses are expected. The financial statements do not reflect any adjustments that might result if the Company was unable to continue as a going concern. The Company anticipates that operating losses will continue in the near term as management continues efforts to acquire income producing assets.

NOTE 4 - COMPARATIVE FINANCIAL STATEMENTS The financial statements include certain prior-year summarized comparative information. Such information does not include all of the information required for financial statements presented in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with the Company’s financial statements for the year ended December 31, 2025, for the six months ended June 30, 2025, and for the six months ending June 30, 2026, from which the summarized information was derived.

NOTE 5 - STOCKHOLDERS’ EQUITY The Company is authorized to issue 10,000,000 shares of preferred stock. At June 30, 2026, and December 31, 2025, no shares of preferred stock were issued or outstanding. The Company is authorized to issue 300,000,000 shares of common stock. At June 30, 2026, and December 31, 2025, there were 59,722,232 and 58,837,232 shares of common stock issued and outstanding, respectively. During the first three months of 2026, the Company issued 885,000 shares of common stock. These issuances consisted of 750,000 shares to Ryan Khouri, 50,000 shares to Katherine Cole, and 85,000 shares to Kevin Sakser. The shares issued to Katherine Cole and Kevin Sakser were issued in exchange for total cash proceeds of $10,800. The shares issued to Ryan Khouri were issued in exchange for services rendered to the Company, valued at $60,000. During 2025, the Company issued 4,767,895 shares of common stock. These issuances consisted of 2,817,895 shares to Katherine Cole, 1,650,000 shares to Ryan Khouri, 100,000 shares to Kevin Sakser, 50,000 shares to Murray Goldenberg, 100,000 shares to Borders Consulting LLC, and 50,000 shares to Frank Hariton. Included in the shares issued to Katherine Cole were 2,532,895 shares issued in exchange for cash of $95,025. All remaining shares issued during 2025 were issued in exchange for services rendered to the Company. These services were valued at $83,849. During 2024, the Company issued 5,840,000 shares of common stock. These issuances consisted of 3,520,000 shares to Ryan Khouri, 1,250,000 shares to Allen Greenspoon, 690,000 shares to John Jennewein, 280,000 shares to Petro Czupiel, and 100,000 shares to Kevin Sakser. All shares issued during 2024 were issued in exchange for services rendered to the Company.

10000000

300000000

59722232

58837232

885000

750000

50000 85000 10800

60000

4767895

2817895

1650000

100000

50000

100000

50000

2532895 95025

83849

5840000

3520000

1250000

690000

280000

100000

NOTE 6 - INTANGIBLE ASSETS At June 30, 2026 and December 31, 2025, intangible assets were as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2026</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31, 2025</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Deferred patent costs</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,313</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,313</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">109,883</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">109,883</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Trademarks</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,564</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,564</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Accumulated amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(60,357 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(56,951 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Intangible assets, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">67,403</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">70,809</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Amortization expenses for six months ended June 30, 2026, and the year ended December 31, 2025, were $3,406 and $6,432, respectively. The Company’s patents are listed below: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Country</td><td> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Patent No.</td><td> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">File Date</td><td> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Expiration Date</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:bottom;">Canada</td><td style="width:2%;"> </td><td style="width:18%;vertical-align:bottom;">2624110</td><td style="width:2%;"> </td><td style="width:18%;vertical-align:bottom;">3/27/2008</td><td style="width:2%;"> </td><td style="width:18%;vertical-align:bottom;">3/27/2028</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">U.S.</td><td> </td><td style="vertical-align:bottom;">8623401</td><td> </td><td style="vertical-align:bottom;">3/27/2008</td><td> </td><td style="vertical-align:bottom;">3/27/2028</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">U.S.</td><td> </td><td style="vertical-align:bottom;">9833461</td><td> </td><td style="vertical-align:bottom;">10/23/2015</td><td> </td><td style="vertical-align:bottom;">10/23/2035</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Canada</td><td> </td><td style="vertical-align:bottom;">2922959</td><td> </td><td style="vertical-align:bottom;">3/3/2016</td><td> </td><td style="vertical-align:bottom;">3/3/2036</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">U.S.</td><td> </td><td style="vertical-align:bottom;">11166912</td><td> </td><td style="vertical-align:bottom;">3/3/2016</td><td> </td><td style="vertical-align:bottom;">3/3/2036</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Europe</td><td> </td><td style="vertical-align:bottom;">17759030.4</td><td> </td><td style="vertical-align:bottom;">2/27/2017</td><td> </td><td style="vertical-align:bottom;">2/27/2037</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Mexico</td><td> </td><td style="vertical-align:bottom;">391622</td><td> </td><td style="vertical-align:bottom;">2/27/2017</td><td> </td><td style="vertical-align:bottom;">2/27/2037</td></tr></tbody></table> The Company also has three trademarks, one in Canada and two in the U.S. The Canada trademark was filed on 11/28/2017 and expires on 11/28/2032. The U.S. trademarks were filed on 5/28/2018 and 11/28/2019 and expire on 5/28/2033 and 11/28/2034, respectively. Intangible assets are recorded at cost and subsequently amortized over the respective useful lives of each, as reflected on the balance sheets. Management believes the reflected value of the intangible assets would substantially increase upon completion of a third-party appraisal.

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30, 2026</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31, 2025</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Deferred patent costs</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,313</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,313</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">109,883</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">109,883</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Trademarks</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,564</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,564</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Accumulated amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(60,357 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(56,951 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Intangible assets, net</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">67,403</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">70,809</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

4313 4313

109883

13564

60357

56951

67403

70809

3406

6432

<table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Country</td><td> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Patent No.</td><td> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">File Date</td><td> </td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Expiration Date</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:18%;vertical-align:bottom;">Canada</td><td style="width:2%;"> </td><td style="width:18%;vertical-align:bottom;">2624110</td><td style="width:2%;"> </td><td style="width:18%;vertical-align:bottom;">3/27/2008</td><td style="width:2%;"> </td><td style="width:18%;vertical-align:bottom;">3/27/2028</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">U.S.</td><td> </td><td style="vertical-align:bottom;">8623401</td><td> </td><td style="vertical-align:bottom;">3/27/2008</td><td> </td><td style="vertical-align:bottom;">3/27/2028</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">U.S.</td><td> </td><td style="vertical-align:bottom;">9833461</td><td> </td><td style="vertical-align:bottom;">10/23/2015</td><td> </td><td style="vertical-align:bottom;">10/23/2035</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Canada</td><td> </td><td style="vertical-align:bottom;">2922959</td><td> </td><td style="vertical-align:bottom;">3/3/2016</td><td> </td><td style="vertical-align:bottom;">3/3/2036</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">U.S.</td><td> </td><td style="vertical-align:bottom;">11166912</td><td> </td><td style="vertical-align:bottom;">3/3/2016</td><td> </td><td style="vertical-align:bottom;">3/3/2036</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Europe</td><td> </td><td style="vertical-align:bottom;">17759030.4</td><td> </td><td style="vertical-align:bottom;">2/27/2017</td><td> </td><td style="vertical-align:bottom;">2/27/2037</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Mexico</td><td> </td><td style="vertical-align:bottom;">391622</td><td> </td><td style="vertical-align:bottom;">2/27/2017</td><td> </td><td style="vertical-align:bottom;">2/27/2037</td></tr></tbody></table> 2624110 3/27/2008 3/27/2028 8623401 3/27/2008 3/27/2028 9833461 10/23/2015 10/23/2035 2922959 3/3/2016 3/3/2036 11166912 3/3/2016 3/3/2036 17759030.4 2/27/2017 2/27/2037 391622 2/27/2017 2/27/2037 11/28/2017 11/28/2032 5/28/2018 11/28/2019 5/28/2033 11/28/2034